期刊文献+

长非编码RNA FBXL19-AS1对急性髓细胞白血病THP-1细胞增殖与侵袭的影响 被引量:3

Effects of long non-coding RNA FBXL19-AS1 on the proliferation and invasion of acute myeloid leukemia THP-1 cells
原文传递
导出
摘要 目的探究长非编码RNA F-box和富含亮氨酸的重复蛋白19反义RNA1 (lnc RNA FBXL19-AS1)在急性髓细胞白血病(acute myeloid leukemia,AML)THP-1细胞中的作用和机制。方法将THP-1细胞随机分为pc-NC组、pc-FBXL19-AS1组以及pc-FBXL19-AS1+miR-339-3p mimic组。pc-NC组转染pc DNA3.0-NC,pc-FBXL19-AS1组转染FBXL19-AS1过表达质粒,pc-FBXL19-AS1+miR-339-3p mimic组共转染FBXL19-AS1过表达质粒以及miR-339-3p模拟物。以细胞计数试剂盒-8(CCK-8)检测THP-1细胞增殖能力,以Transwell实验检测THP-1细胞侵袭能力,以蛋白质印迹法检测SKI原癌基因(SKI)表达。结果 72 h时,pc-NC组和pc-FBXL19-AS1组光密度分别为0.60±0.05和0.78±0.07;pc-NC组和pc-FBXL19-AS1组的侵袭细胞数分别为75.00±6.38和120.67±9.18;pc-NC组、pc-FBXL19-AS1组和pc-FBXL19-AS1+miR-339-3p mimic组中SKI蛋白表达水平分别为1.03±0.10,2.08±0.21和1.68±0.11;以上数据,pc-NC组和pc-FBXL19-AS1组相比,pc-FBXL19-AS1+miR-339-3p mimic组与pc-FBXL19-AS1组相比,差异均有统计学意义(均P <0.05)。此外,双荧光素酶报告基因实验表明FBXL19-AS1可直接靶向miR-339-3p。结论 FBXL19-AS1可促进THP-1细胞的增殖与侵袭,FBXL19-AS1可靶向miR-339-3p上调SKI的表达。 Objective To investigate the role and mechanism of long noncoding RNA F-box and leucine rich repeat protein 19 antisense RNA1(IncRNA FBXL19-AS1) in acute myeloid leukemia(AML) THP-1 cells.Methods THP-1 cells were divided into 3 groups:pc-NC group,pc-FBXL19-AS1 group,and pc-FBXL19-AS1+miR-339-3 p mimic group.pc-NC group was transfected with pcDNA3.0-NC,pc-FBXL19-AS1 group was transfected with FBXL19-AS1 overexpression plasmid,pc-FBXL19-AS1+miR-339-3 p mimic group was co-transfected with FBXL19-AS1 overexpression plasmid and miR-339-3 p mimic.Cell counting kit-8(CCK-8) was performed to detect the proliferation of THP-1 cells.Transwell assay was implemented to detect the invasion of THP-1 cells.Western blot was executed to detect SKI proto-oncogene(SKI) expression.Results At 72 h,the optical density of pc-NC group and pc-FBXL19-AS1 group were 0.60±0.05 and 0.78±0.07,respectively;the number of invasive cells were 75.00±6.38 and 120.67±9.18,respectively;the expression levels of SKI protein in the pc-NC group,pc-FBXL19-AS1 group,and pc-FBXL19-AS1+miR-339-3 p mi group were 1.03±0.10,2.08±0.21 and 1.68±0.11.Compared between pc-NC group and pc-FBXL19-AS1 group,pc-FBXL19-AS1+miR-339-3 p mimic group and pc-FBXL19-AS1 group,the differences of the factors were significant(all P <0.05).In addition,the dual-luciferase reporter gene experiment showed that FBXL19-AS1 can directly target miR-339-3 p.Conclusion FBXL19-AS1 can promote the proliferation and invasion of THP-1 cells,and FBXL19-AS1 can target miR-339-3 p to up-regulate the expression of SKI.
作者 张文芳 周娟 许莹 高清平 毛汉文 ZHANG Wen-fang;ZHOU Juan;XU Ying;GAO Qing-ping;MAO Han-wen(Department of Hematology and Endocrinology,Fifth Hospital in Wuhan,Wuhan 430050,Hubei Province,China;Department of Internal Medicine,Fifth Hospital in Wuhan,Wuhan 430050,Hubei Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2021年第19期2652-2654,2667,共4页 The Chinese Journal of Clinical Pharmacology
关键词 长非编码RNA F-box和富含亮氨酸的重复蛋白19反义RNA 1 急性髓细胞白血病 增殖 侵袭 long noncoding RNA F-box and leucine rich repeat protein 19 antisense RNA 1 acute myeloid leukemia proliferation invasion
  • 相关文献

参考文献7

二级参考文献25

  • 1YANADA M, BORTHAKUR G, GARCIA -MANERO G, et al. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia [ J ]. Leuk Res, 2008, 32 (10) : 1505 - 1509.
  • 2YANADA M, BORTHAKUR G, RAVANDI F, et al. Kinetics of bone marrow blasts during Induction and achievement of complete remission in acute myeloid leukemia [ J ]. Haematologica, 2008, 93 (8) : 1263 - 1265.
  • 3GONEN C, HAZNEDAIIOGLU I C, AKSU S, et al. Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia [J]. Platelets, 2005, 16 (1): 31-37.
  • 4HAZNEDAROGLU I C, GOKER H, TURGUT M, et al. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions [ J]. Clin Appl Thromb Hemost, 2002, 8 (3): 193 -212.
  • 5MALKAN U Y, GUNES G, ISIK A, et al. Rebound thrombocytosis following induction chemotherapy is an independent predictor of a good prognosis in acute myeloid leukemia patients attaining first complete remission [J]. Acta Haematol, 2015, 134 (1): 32-37.
  • 6VARDIMAN J W, HARRIS N L, BRUNNING R D. The World Health Organization (WHO) classification of the myeloid neoplasma [J]. Blood, 2002, 100 (7): 2292-2302.
  • 7APPELBAUM F R, GUNDACKER H, HEAD D R, et al. Age and acute myeloid leukemia [ J ]. Blood, 2006, 107 ( 9 ) : 3481 - 3485.
  • 8YANADA M, GARCIA - MANERO G, BORTHAKUR G, et al. Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission [J]. Cancer, 2007, 110 (12) : 2756 - 2760.
  • 9YANADA M, OHTAKE S, MIYAWAKI S, et ab The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies [J]. Cancer, 2013, 119 (18) : 3326 -3333.
  • 10BHATNAGAR B, GARZON R. The use of molecular geneties to refine prognosis in acute myeloid leukemia [J]. Curr Hematol Malig Rep, 2014, 9 (2): 148-157.

共引文献44

同被引文献40

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部